Association Between Efavirenz as Initial Therapy for HIV-1 Infection and Increased Risk for Suicidal Ideation or Attempted or Completed Suicide
Authors:
- 1 July 2014
- journal article
- research article
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 161 (1) , 1-10
Abstract
This article has been corrected. The original version (PDF) is appended to this article as a Supplement. The relationship between efavirenz use and suicidality is not well-defined. To compare time to suicidality with efavirenz-containing versus efavirenz-free antiretroviral regimens for initial treatment of HIV. Participant-level data were analyzed from 4 AIDS Clinical Trials Group, antiretroviral-naive studies conducted from 2001 to 2010. Within each study, participants were randomly assigned to an efavirenz-containing (n = 3241) or efavirenz-free (n = 2091) regimen. (ClinicalTrials.gov: NCT00013520 [A5095], NCT00050895 [A5142], NCT00084136 [A5175], and NCT00118898 [A5202]) AIDS Clinical Trials Group sites; 74% of participants enrolled in the United States. Antiretroviral-naive participants. Efavirenz versus efavirenz-free regimens. Suicidality was defined as suicidal ideation or attempted or completed suicide. Groups were compared with a hazard ratio and 95% CI estimated from a Cox model, stratified by study. Seventy-three percent of participants were men, the median age was 37 years, and 32% had documented psychiatric history or received psychoactive medication within 30 days before entering the study. Median follow-up was 96 weeks. Suicidality incidence per 1000 person-years was 8.08 (47 events) in the efavirenz group and 3.66 (15 events) in the efavirenz-free group (hazard ratio, 2.28 [95% CI, 1.27 to 4.10]; P = 0.006). Incidence of attempted or completed suicide was 2.90 (17 events) and 1.22 (5 events) in the efavirenz and efavirenz-free groups, respectively (hazard ratio, 2.58 [CI, 0.94 to 7.06]; P = 0.065). Eight suicides in the efavirenz group and 1 in the efavirenz-free group were reported. There was not a standardized questionnaire about suicidal ideation or attempt. Efavirenz was open-label in 3 of 4 studies. Initial treatment with an efavirenz-containing antiretroviral regimen was associated with a 2-fold increased hazard of suicidality compared with a regimen without efavirenz. National Institutes of Health.Keywords
This publication has 48 references indexed in Scilit:
- Efficacy and Safety of Three Antiretroviral Regimens for Initial Treatment of HIV-1: A Randomized Clinical Trial in Diverse Multinational SettingsPLOS Medicine, 2012
- Discontinuation of Atripla as first-line therapy in HIV-1 infected individualsAIDS, 2012
- Prevention of HIV-1 Infection with Early Antiretroviral TherapyNew England Journal of Medicine, 2011
- A Systematic Review of the Psychiatric Side-Effects of EfavirenzAIDS and Behavior, 2011
- Long-Term Impact of Efavirenz on Neuropsychological Performance and Symptoms in HIV-Infected Individuals (ACTG 5097s)HIV Research & Clinical Practice, 2009
- Stigma, social support, and depression among people living with HIV in ThailandAIDS Care, 2009
- Cross-national prevalence and risk factors for suicidal ideation, plans and attemptsThe British Journal of Psychiatry, 2008
- Use of Efavirenz Is Not Associated with a Higher Risk of Depressive Disorders: A Substudy of the Randomized Clinical Trial ALIZE-ANRS 099Clinical Infectious Diseases, 2006
- Impact of HIV-Related Stigma on Health Behaviors and Psychological Adjustment Among HIV-Positive Men and WomenAIDS and Behavior, 2006
- Triple-Nucleoside Regimens versus Efavirenz-Containing Regimens for the Initial Treatment of HIV-1 InfectionNew England Journal of Medicine, 2004